SEC Comment Letter for NOVAVAX INC (NVAX) (CIK 0001000694) (NVAX) — Jan 6, 2020

NOVAVAX INC (NVAX) (CIK 0001000694)
Date: Jan. 6, 2020 · CIK: 0001000694 · Accession: 0000000000-20-000102

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-235761

Date

January 6, 2020

Author

Not clearly detected

Form

UPLOAD

Company

NOVAVAX INC (NVAX) (CIK 0001000694)

Letter

January 6, 2020 John A. Herrmann, III Senior Vice President and General Counsel Novavax, Inc. 21 Firstfield Road Gaithersburg, Maryland 20878 Re:Novavax, Inc. Registration Statement on Form S-3 Filed December 31, 2019 File No. 333-235761 Dear Mr. Herrmann: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Paul M. Kinsella

Show Raw Text

January 6, 2020
John A. Herrmann, III
Senior Vice President and General Counsel
Novavax, Inc.
21 Firstfield Road
Gaithersburg, Maryland 20878
Re:Novavax, Inc.
Registration Statement on Form S-3
Filed December 31, 2019
File No. 333-235761
Dear Mr. Herrmann:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Paul M. Kinsella

SecProbe.io